Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
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
NHb3zrDjTyBpteDW
